NCT05092945Completed
Brown Adipose Tissue Metabolism in Type 2 Diabetes
Quantifying Brown Adipose Tissue Thermogenesis in Type 2 Diabetes
Source: ClinicalTrials.gov · Last updated 12 Feb 2026
Brief summary (registry, in English)
Activation of brown adipose tissue (BAT) by cold exposure. BAT thermogenesis and BAT volume of metabolic activity will be assessed by Positron-Emitting-Tomography (PET/CT) and MRI/MRS imaging and new pharmacological methods to modulate BAT thermogenesis. All previous data on the functioning of Brown Adipose Tissue (BAT) were obtained by Positron-Emitting-Tomography (PET) imaging studies using fluorodeoxyglucose F18 ( \[18F\]- FDG). This approach underestimates the actual activity of the BAT. In this study, the investigator is going to use a new PET tracer (C11-palmitate) which is a fat molecule. This will allow to quantify more accurately the activity of brown fat.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 6 (actual)
- First submitted
- 19 May 2021
- Start date
- 18 May 2021
- Primary completion date
- 10 Feb 2022
- Lead sponsor
- Université de Sherbrooke
- Diseases
- Type 2 diabetes
- NCT number
- NCT05092945
What you commit to
- Study type: Interventional
- Participants enrolled: 6
- From 18 May 2021 to the primary completion date, 10 Feb 2022
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Treatment with a fibrate, thiazolidinedione, insulin, beta-blocker, GLP-1 agonist, or other drug known to affect lipid or carbohydrate metabolism, except statins, metformin, sulfonylurea, DPP-IV inhibitor and other antihypertensive agents that can be temporarily stopped safely prior to the studies, as per our approved protocols;
- Having participated to a research study with exposure to radiation in the last two years before the start of the study.
Other illness
- Presence of overt cardiovascular, liver, renal or other medical conditions;
- Any other contraindication to temporarily suspending current medications for lipids or hypertension;
Other
- Change in weight of more than 2 kg over the past 3 months or recent changes in lifestyle;
- Smoking or consumption of more than 2 alcoholic beverages per day;
- Any contraindication to MRI scanning.
Who the study is looking for
- 10 men and 10 women with T2D.
- 10 non-diabetic men and 10 non-diabetic women (matched for sex, BMI and age to the T2D participants).
Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre de recherche du CHUS Coordinator of this site? Confirm its status | Sherbrooke | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.